Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201217 | 0.89 | PRMT6 (0.39) | ALDH1A1APOBEC3GPRMT6PRMT1PRMT8 | |
| SCHEMBL16201390 | 0.87 | PRMT6 (0.39) | ALDH1A1PRMT6PRMT1PRMT8 | |
| SCHEMBL16201375 | 0.87 | NISCH (0.36) | PRMT6PRMT1PRMT8MOK | |
| SCHEMBL16201366 | 0.85 | PRMT6 (0.36) | PRMT6PRMT1PRMT8 | |
| SCHEMBL16201378 | 0.84 | PIM1 (0.33) | ALDH1A1PRMT6PRMT1PRMT8MOK | |
| SCHEMBL16201347 | 0.83 | CRHR1 (0.38) | ALDH1A1PRMT1 | |
| SCHEMBL16201412 | 0.83 | PRMT6 (0.49) | PRMT6PRMT1PRMT8S1PR1S1PR3 | |
| SCHEMBL16125841 | 0.82 | NOTUM (0.41) | PRMT6PRMT1PRMT8 | |
| SCHEMBL16201421 | 0.82 | MEN1 (0.36) | ALDH1A1PRMT6PRMT1PRMT8MOK | |
| SCHEMBL16201373 | 0.81 | STK4 (0.44) | ALDH1A1APOBEC3GPRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885APOBEC3G 2366/4885PRMT6 4/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 895/4885APOBEC3G 2231/4885PRMT6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.